Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Theresa Smith

Nurse Practitioner, Family Lewiston, ID Nurse Practitioner

NPI 1740331842 CMS profile 10987556

1522 17Th St, Lewiston, ID 83501

Open in the dashboard

General payments

$3,711

236 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Theresa Smith of Lewiston, ID is reported in the CMS Open Payments database as having received $3,711 across 236 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,216 77
2024 General $1,167 81
2023 General $391 21
2022 General $911 55
2021 General $26 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Theresa Smith
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Theresa Smith were reported at $1,216. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Theresa Smith Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $26 $124 $35–$379 $132
2022 $911 $141 $44–$430 $149
2023 $391 $154 $49–$476 $160
2024 $1,167 $165 $51–$504 $164
2025 $1,216 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $637 42 payments
  2. Pfizer Inc. $611 47 payments
  3. AstraZeneca Pharmaceuticals LP $473 16 payments
  4. GlaxoSmithKline, LLC. $427 44 payments
  5. Novo Nordisk Inc $204 12 payments
  6. Amgen Inc. $167 10 payments
  7. Otsuka America Pharmaceutical, Inc. $142 7 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $131 6 payments
  9. Biohaven Pharmaceutical Holding Company Ltd. $126 13 payments
  10. Exact Sciences Corporation $91 3 payments
  11. Other $701 36 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,711 236 payments
Products named General payments · program years 2021–2025
  1. NURTEC ODT $558 43 payments
  2. ZAVZPRET $427 27 payments
  3. TRELEGY ELLIPTA $420 42 payments
  4. QULIPTA $395 27 payments
  5. UBRELVY $369 27 payments
  6. BREZTRI $300 6 payments
  7. AIRSUPRA $288 9 payments
  8. FARXIGA $267 4 payments
  9. ELIQUIS $171 19 payments
  10. REXULTI $142 7 payments
  11. Other $2,006 112 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 194 drugs

Part D claims

14,499

Median for Nurse Practitioner: 389

Drug cost

$1,004,097

Median for Nurse Practitioner: $21,885

Branded share of claims

22.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 123 $117,269
Eliquis Apixaban Brand 171 $116,593
Farxiga Dapagliflozin Propanediol Brand 135 $112,431
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 92 $68,589
Jardiance Empagliflozin Brand 40 $46,282
Nurtec Odt Rimegepant Sulfate Brand 18 $39,739
Mounjaro Tirzepatide Brand 41 $39,714
Xarelto Rivaroxaban Brand 45 $38,369
Myrbetriq Mirabegron Brand 55 $33,856
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 39 $25,215

The 10 drugs with the highest cost, of 194 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 95 billing codes

Paid by Medicare

$136,724

Of which drugs: $39,622

Medicare patients

477

Average age 74

Services billed

5,842

306 women, 171 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 39%
Diabetes 30%
Chronic kidney disease 23%
COPD 21%
Ischemic heart disease 19%
Atrial fibrillation 17%
Depression 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 16 1,200 $24,819
Vaccine for influenza for injection into muscle 90662 Office 79 83 $6,732
Pcv20 vaccine im 90677 Office 17 17 $4,947
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 17 54 $49

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $176
$176 92 —
NURTEC ODT
  • PFIZER INC. $141
$141 18 —
ZAVZPRET
  • PFIZER INC. $117
$117 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $97
$97 — —
QULIPTA
  • AbbVie, Inc. $84
$84 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

236 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Idaho

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record